Therapeutic Asset Ratings

137 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
h3b-6545 Breast Neoplasms	Eisai Co., Ltd.	P1/2	CCC (53)
Benadryl Breast Neoplasms	Merck Sharp & Dohme LLC	P3	CCC (52)
DEXTROSE Breast Neoplasms	Merck Sharp & Dohme LLC	P3	CCC (52)
hlx11 Breast Neoplasms	Shanghai Henlius Biotech	P3	CCC (52)
IBUPROFEN Breast Neoplasms	Aga Khan University	P3	CCC (52)
Lorazepam Breast Neoplasms	Merck Sharp & Dohme LLC	P3	CCC (52)
ly4064809 Breast Neoplasms	Eli Lilly and Company	P3	CCC (52)
Pumitamig Breast Neoplasms	BioNTech SE	P3	CCC (52)
Sacituzumab Tirumotecan Breast Neoplasms	Merck Sharp & Dohme LLC	P3	CCC (52)
Alpelisib Breast Neoplasms	Borstkanker Onderzoek Groep	P2	CCC (52)
arx788 Breast Neoplasms	Ambrx, Inc.	P2	CCC (52)
Cediranib Breast Neoplasms	National Cancer Institute (NCI)	P2	CCC (52)
Elacestrant Breast Neoplasms	Kristina A. Fanucci	P2	CCC (52)
Enzalutamide Breast Neoplasms	Nuvation Bio Inc.	P2	CCC (52)
Panobinostat Breast Neoplasms	Dana-Farber Cancer Institute	P2	CCC (52)
Trebananib Breast Neoplasms	QuantumLeap Healthcare Collaborative	P2	CCC (52)
Vepdegestrant Breast Neoplasms	Pfizer	P2	CCC (52)
Axitinib Breast Neoplasms	Lynkcell Europe	P1/2	CCC (52)
Iza-Bren Breast Neoplasms	Bristol-Myers Squibb	P2/3	CCC (50)
Tucidinostat Breast Neoplasms	Shengjing Hospital	P2/3	CCC (50)
Atezolizumab Breast Neoplasms	Dana-Farber Cancer Institute	P1/2	CCC (49)
ARX 788 Breast Neoplasms	Shengjing Hospital	P2	CCC (48)
Atirmociclib Breast Neoplasms	Pfizer	P2	CCC (48)
Dan-222 Breast Neoplasms	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Datopotamab Deruxtecan Breast Neoplasms	QuantumLeap Healthcare Collaborative	P2	CCC (48)

Showing 51 to 75 of 137 assets

PreviousPage 3 of 6Next